Global practices of meningococcal vaccine use and impact on invasive disease
| Autor: | Carol Tevi-Benissan, Shao Zhujun, Rabab Z. Jafri, Jon S. Abramson, David N Durrheim, Asad Ali, Juhani Eskola, Keith P. Klugman, Florence Fermon, Nancy E. Messonnier, Samba O. Sow, Zulfiqar A Bhutta, Mary Ramsay |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Meningococcal Vaccines Review Meningococcal vaccine Disease Meningitis Meningococcal Neisseria meningitidis Global Health Meningococcal disease Mass Vaccination Microbiology Polysaccharides Conjugate vaccine Environmental health Epidemiology medicine Humans Vaccines Conjugate Immunization Programs business.industry Incidence Incidence (epidemiology) Public Health Environmental and Occupational Health General Medicine medicine.disease Virology Meningococcal Infections Vaccination Infectious Diseases Female Parasitology business Meningitis |
| Zdroj: | Pathogens and Global Health. 108:11-20 |
| ISSN: | 2047-7732 2047-7724 |
| DOI: | 10.1179/2047773214y.0000000126 |
| Popis: | A number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated meningococcal vaccines have lead to control of serogroup C meningococcal disease in the UK, Canada, Australia, Spain, Belgium, Ireland, and Iceland. Serogroup B disease, predominant in New Zealand, has been dramatically decreased, partly due to the introduction of an outer membrane vesicle (OMV) vaccine. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. The highest incidence region of the meningitis belt initiated vaccination with the serogroup A conjugate vaccine in 2010 and catch-up vaccination is ongoing. Overall results of this vaccine introduction are encouraging especially in countries with a moderate to high level of endemic disease. Continued surveillance is required to monitor effectiveness in countries that recently implemented these programs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|